EuroMedtech™ 2012 Press Releases

April 24, 2012EuroMedtech™ 2012 in Grenoble is welcomed by region's BioCluster membersCutting-edge medtech business leaders and senior executives set to attend
EBD Group, the leading partnering firm for the life science industry, will host the fourth annual EuroMedtech™ international medtech partnering conference in Grenoble, France May 31–June 1, 2012 at the Convention Center of the WTC Grenoble. "We are excited to hold EuroMedtech in Grenoble this year, as the city is home to a fast-growing life science industry," said Carola Schropp,...more ►

February 29, 2012EuroMedtech™ 2012 partnering forum in Grenoble to jump-start collaborations in the rapidly evolving medtech industry The fourth annual EuroMedtech™ 2012 partnering conference to be held in Grenoble, France May 31–June 1, 2012 at the Convention Center of the World Trade Center Grenoble will bring together leaders and decision makers from the international medical technology industry eager to participate in one-to-one partnering meetings. The conference is focused on providing collaboration opportuni...more ►

December 5, 2011EuroMedtech™ 2012 looks to set new benchmark for productive partnering Leaders from the international medical technology industry will gather May 31 to June 1, 2012 in Grenoble, France for the fourth annual EuroMedtech™ partnering conference. In 2011, the conference played host to more than 260 delegates representing 205 companies from 27 countries who engaged in 741 one-to-one partnering meetings. In addition, there were eight workshops and panel sessions an...more ►

1 May 2012 Epizyme: Intensive dealmaking in pursuit of personalized therapeutics Little was known about the branch of epigenetics called histone methyltransferases (HMTs) when Epizyme began in late 2007. Yet before the company presented the world's first animal demonstration of efficacy for HMTs in July 2011, it had already attracted USD 54 million in venture investment and USD 45 million in funding from two pharma partners and two foundations. more ►

20 April 2012 EU medtech management and oversight: New, but complex, proposals A clear, transparent, single mechanism for the oversight and coordination of medtech rules is needed to restore confidence in the European medtech regulatory system which has been badly undermined by recent product safety scandals. more ►

25 March 2012 GSK, J&J back USD 200 million fund for early stage assets The chairmen of Johnson & Johnson Pharmaceuticals and GlaxoSmithKline R&D announced a trailblazing venture fund for fast-tracking early stage assets during the closing plenary session at BIO-Europe Spring^® in Amsterdam. more ►

25 March 2012 Investors more confident, but selective with biotechs The biotech sector continues to outperform other industries in public equity markets in the United States, but private equity is more selective about opportunities, according to Biotechnology Industry Organization (BIO). more ►

22 March 2012 Examining major deals of 2011 with the real dealmakers Lead executives with four of the headline-grabbing deals of the past year shared insights into the negotiation with participants at BIO-Europe Spring^® in Amsterdam. more ►